PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Besse, Benjamin
TI  - Management of Targeted Drug Resistance in NSCLC
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 24--25
VI  - 14
IP  - 3
4099  - http://mdc.sagepub.com/content/14/3/24.short
4100  - http://mdc.sagepub.com/content/14/3/24.full
AB  - In some cases of non—small cell lung cancer (NSCLC), mutations in oncogenes appear to be the underlying mechanism of lung cancer development. Specifically targeted therapies are promising in the treatment of NSCLC, but mutations in oncogenic drivers can result in drug resistance. This article discusses drug resistance to ALK and ROS1 inhibitors, as well as BRAF and HER2 mutations that result in drug resistance.